## THE LONG ROAD TO TREATMENT

## Medicare's CED Clinical Trial Policy Delays Patient Access

In an unprecedented decision, Medicare strictly limited coverage of new monoclonal antibody Alzheimer's therapies approved by FDA under Accelerated Approval for many living with mild Alzheimer's Disease. Under this new drug Coverage with Evidence Development (CED) policy, it could take up to 3 years after a new drug is approved before patients have the opportunity to enroll in a qualifying CED clinical trial and receive treatment. At each step of the CED clinical trial process, there are multiple instances where patients could fail to receive the treatment they need.



**CMS Sets** Up NCD with CED O (9 to 12 months)

Outreach


to patients

**Screening** for clinical trial eligibility

CED clinical trial: 18-24 -month process

2000 **PEOPLE A DAY PROGRESS FROM MILD TO MODERATE ALZHEIMER'S** DISEASE.

Set up



Very few spots available

**Enrollment** 

rejected -Dead end: no

**Enrollment** 

confirmed

- Limits on providers
- Limited locations/ Poor to no rural access





**SPONSOR FOLLOW-UPS** & REPORTING **TO CMS** 





VISITS.

**Assigned** to Placebo-

Medicare beneficiaries shouldn't have to wait to recieve FDAapproved treatments. CED requirements are not the answer.

& OTHER REQUIRED

Learn more at www.fightchronicdisease.org.